This is the authors' abstract. We don't add key points for this paper.
A low dose (0.5 mg) of thyrotropin-releasing hormone (TRH), a short-acting tripeptide with known analeptic properties, was administered to eight depressed patients 5 minutes after ECT session 3 or 4 in a double-blind, placebo-controlled crossover design. After TRH infusion the patients displayed selectively better performance on a battery of neuropsychological tests than they did after placebo infusion. Further exploration with pharmacological probes to mitigate ECT postictal cognitive deficits is warranted.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Khan et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: